Rosenberg at the National Cancer Institute/NIH. Belldegrun served as a research fellow in surgical oncology and immunotherapy under Dr. ![]() Belldegrun is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He serves as Executive Chairman of Allogene Chairman of Two River Group and Kronos Bio Co-Founder and Senior Managing Director of Vida Ventures, a life science venture group.ĭr. Belldegrun most recently co-founded Allogene Therapeutics, a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (CAR T) therapies for cancer. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer.ĭr. Belldegrun has had a distinguished tenure in the life sciences and has been closely involved with the founding and advancement of several successful biopharmaceutical companies, including Cougar Biotechnology and Agensys. Belldegrun founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017.ĭr. He has built a distinguished career as a visionary surgeon, scientist, and life sciences entrepreneur.ĭr. ![]() Belldegrun is the Chairman of UroGen Pharma and has served as our Chair since December 2012.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |